IGF-I，游離 ELISA-IGF-I, Free ELISA代理/參數(shù)/廠家-ELISA試劑盒-艾美捷科技有限公司

PRODUCT CENTER

ELISA試劑盒

產(chǎn)品中心

當(dāng)前位置：首頁(yè) > 產(chǎn)品中心 > 免疫學(xué)產(chǎn)品 > ELISA試劑盒

中文名稱: IGF-I，游離 ELISA

英文名字: IGF-I, Free ELISA

供應(yīng)商: Ansh Labs

產(chǎn)品貨號(hào): AL-122

產(chǎn)品報(bào)價(jià): ￥詢價(jià)/96wellmicrotiter

產(chǎn)品說(shuō)明書(shū): 點(diǎn)擊查看

購(gòu)買(mǎi)方式: 90%產(chǎn)品中國(guó)有現(xiàn)貨庫(kù)存。銀行轉(zhuǎn)賬、電匯、支票、現(xiàn)金，在線支付寶及網(wǎng)銀支付，或直接與我們電話聯(lián)系400-6800-868

產(chǎn)品新聞

背景資料: Insulin-like growth factor I (IGF-I, a.k.a. somatomedin C) is a 7.6 kDa, 70 amino acid residue peptide, which mediates the actions of growth hormone (GH).1 IGF-I is synthesized as a prohormone, a polypeptide consisting of A, C, B, D, and E domains.1, 2 After post-translational modification, the mature IGF-I consist of the A, C, B and D domains, and is structurally homologous to IGF-II and insulin. In vivo, IGF-I is secreted by the liver and several other tissues and is postulated to have mitogenic and metabolic actions at or near the sites of synthesis; i.e. paracrine effects.1 IGF-I also appears in the peripheral circulation where it circulates primarily in a high molecular weight tertiary complex with IGF-binding protein-3 (IGFBP-3) and acid-labile subunit (ALS).2,3 A smaller proportion of IGF-I circulates in association with other IGF-binding proteins.3
n
nRecently, there has been research interest in the measurement of serum/plasma "unbound" IGF-I which, theoretically, is the biologically active fraction. Although the existence of a true unbound IGF serum/plasma compartment is controversial, pharmacokinetic studies indicate that a small percentage of plasma IGF-I is not associated with IGF-binding proteins.4,5 Unbound IGF-I has also been observed in saliva.6 In addition, it appears that IGF-I may exert a tonic hypoglycemic effect under normal conditions that is inhibited by exogenous IGFBP-1 administration.7
n
nIt is likely that the measured unbound IGF-I fraction is a combination of the true unbound and the fraction of IGF-I that can be readily dissociated from IGFBP's under the specific assay conditions. In this respect, it has been shown that exogenously administered IGF-I almost immediately associates with low MW IGFBP's, then quickly moves into the high MW tertiary complex.5,8,9 The tertiary complex does not appear to be easily dissociated and does not re-equilibrate with exogenously added IGF-I or IGFBP-3 to a significant degree.8 On the other hand, the low MW complexes have a rapid turnover, and may be the source for much of the measured unbound IGF-I.
n
nVarious methods have been used to estimate the unbound (or freely dissociated) IGF-I fraction.4,9,10 Size-exclusion chromatography and filtration methods.4,9 have the theoretical disadvantage of altering the sample matrix and the equilibrium between IGF-I and IGFBP's. A direct detection unbound IGF-I assay using immobilized IGFBP-3 for capture and anti-IGF-I antibody for detection has been reported.11
n
nThe Ansh Labs Free IGF-I kit uses a highly sensitive two-site antibody method which allows detection of unbound IGF-I. The kit may be used as a "direct" assay to measure the "dissociable" fraction of IGF-I.8
n
nReferences:
n1. Daughaday E, Rotwein P: Insulin like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations. Endocrin Rev 10:68-91, 1989.
n2. Baxter RC, Martin JL, Beniac VA: High molecular weight insulin-like growth factor binding protein complex. J Biol Chem 264:11843-11848, 1989.
n3. Rechler M: Insulin-like growth factor binding proteins. Vit Horm 47:1-114, 1993.
n4. Guler HP, Zapf J, Froesch ER: Short-term metabolic effects of recombinant human insulin-like growth factor-I in healthy adults. New Engl J Med 317:137-140, 1987.
n5. Zapf J, Hauri C, Waldvogel M, Froesch ER: Acute metabolic effects and half-lives of intravenously administered insulinlike growth factors I and II in normal and hypophysectomized rats. J Clin Invest 77:1768-1775, 1986.
n6. Costigan DC, Guyda HJ, Posner BI: Free insulin-like growth factor I (IGF-I) and IGF-II in human saliva. J Clin Endocrinol Metab 66:1014-1018, 1988.
n7. Lewitt MS, Denyer GS, Cooney GJ, Baxter RC: Insulin-like growth factor-binding protein-1 modulates blood glucose levels. Endocrinology 129:2254-2256, 1991.
n8. Lewitt MS, Saunders H, Baxter RC: Bioavailability of insulin-like growth factors (IGFs) in rats determined by the molecular distribution of human IGF-binding protein-3. Endocrinology 133:1797-1802, 1993.
n9. Lieberman SA, Bukar J, Chen SA, Celniker AC, Compton PG, Cook J, Albu J, Perlman AJ, Hoffman AR: Effects of recombinant human insulin-like growth factor-I (rhIGF-I) on total and free IGF-I concentrations, IGF-binding proteins, and glycemic response in humans. J Clin Endocrinol Metab 75:30-36, 1992.
n10. Lee PDK, Powell D, Baker B, Liu F, Mathew G, Levitsky I, Gutierrez OD, Hintz RL: Characterization of a direct, non-extraction immunoradiometric assay for free IGF-I. Presented at the 76th annual meeting of the Endocrine Society, Anaheim, 1994.
n11. Mukku VR: A 96-well microtiter plate assay for free IGF-I in plasma using immobilized IGFBP-3. Presented at the 73rd annual meeting of The Endocrine Society, Washington, D.C., 1991. (abstract #462).
n12. HHS Publication, 5th ed., 2007. Biosafety in Microbiological and Biomedical Laboratories. Available http://www.cdc.gov/biosafety/publications/bmbl5/BMBL5
n13. DHHS (NIOSH) Publication No. 78–127, August 1976. Current Intelligence Bulletin 13 - Explosive Azide Hazard. Available http:// www.cdc.gov/niosh.
n14. Kricka L. Interferences in immunoassays – still a threat. Clin Chem 2000; 46: 1037–1038.

產(chǎn)品描述: The Free IGF-I enzyme linked immunosorbent assay (ELISA) kit provides materials for the quantitative measurement of Free IGF-I in serum and other biological fluids.

產(chǎn)品特點(diǎn)

保存建議: Store at 2 to 8°C until expiration date.

其他: Ansh labs是開(kāi)發(fā)和生產(chǎn)免疫檢測(cè)試劑盒和定制生物技術(shù)檢測(cè)產(chǎn)領(lǐng)創(chuàng)者，總部位于美國(guó)休斯敦，公司產(chǎn)品遍及全球80多個(gè)國(guó)家。公司于2011年成立，核心團(tuán)隊(duì)來(lái)自于Diagnostic system laboratory，專注于女性健康和激素檢測(cè)領(lǐng)域近40年，擁有全球領(lǐng)先的核心技術(shù)，以及多年經(jīng)驗(yàn)生物技術(shù)研發(fā)經(jīng)驗(yàn)的科學(xué)家團(tuán)隊(duì)，產(chǎn)品覆蓋生殖健康，高危妊娠，腫瘤，糖尿病等多個(gè)疾病領(lǐng)域，圍繞最新的免疫分析技術(shù)，多種蛋白和單克隆抗體，如AMH，BMP-15, Follistatin, GDF-9, IGF-I, IGF-II, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5, Inhibin Alpha, Inhibin ?A, Inhibin ?B, MBP, PAPP-A, PAPP-A2 and Vitamin D.等幾十余種試劑產(chǎn)品，也同時(shí)涵蓋小鼠，大鼠，狗，羊，牛等靈長(zhǎng)類多個(gè)物種的獨(dú)特的物種特異性的試劑。 Ansh labs 坐落于美國(guó)德克薩斯州，是目前世界上唯一能提供TGF-β超家族所有成員的檢測(cè)公司，也是最早專注激素類產(chǎn)品研究和新型免疫檢測(cè)技術(shù)的先驅(qū)者。優(yōu)勢(shì)產(chǎn)品涉及TGF-β super family、AMH/抑制素B(human/animal)、full panel IGFs、以及最完整的胰高血糖素系列。